New research refutes speculation that NSAIDs can negatively impact patients with COVID-19.
New CMS waivers grant hospitals and healthcare systems a number of temporary flexibilities designed to help manage the COVID-19 pandemic.
The FDA issued emergency use authorization for anti-malarial drugs hydroxychloroquine and chloroquine to treat COVID-19 patients when deemed appropriate by a healthcare provider.
New York Governor Andrew Cuomo has issued an Executive Order granting immunity to healthcare providers responding to the COVID-19 pandemic. Here’s MLMIC’s statement on its meaning and significance.